Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-Label, Safety, Tolerability and Exposure Study of Oral (Z)-Endoxifen for the Treatment of Gonadotropin-Independent Precocious Puberty in Girls With McCune-Albright Syndrome

NCT07869732 is registered in ClinicalTrials.gov with Atossa Therapeutics, Inc. as lead sponsor.

NCT NCT07869732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07869732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-Label, Safety, Tolerability and Exposure Study of Oral (Z)-Endoxifen for the Treatment of Gonadotropin-Independent Precocious Puberty in Girls With McCune-Albright Syndrome
Lead sponsor
Atossa Therapeutics, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2027
Completion date
September 30, 2028
Enrollment
6 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

precocious puberty, gonadotropin-dependent